Monoclonal Antibodies (MAs) Global Market 2024 – By Growth, Drivers, Growth Trends, Analysis Forecast To 2033 | Johnson & Johnson, Merck & Co. Inc., AbbVie Inc

The Monoclonal Antibodies (MAs) Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Monoclonal Antibodies (MAs) Market:
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

According to The Business Research Company’s Monoclonal Antibodies (MAs) Global Market Report 2024, The monoclonal antibodies (mabs) market size has grown rapidly in recent years. It will grow from $234.37 billion in 2023 to $261.66 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%.  The growth in the historic period can be attributed to prevalence of chronic diseases, increasing investment in r&d, growing awareness of mabs, growing elderly population.

The monoclonal antibodies (mabs) market size is expected to see rapidly grown in the next few years. It will grow to $424.24 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%.  The growth in the forecast period can be attributed to expanding therapeutic indications, personalized medicine, biosimilars and generics, combination therapies, pandemic preparedness, biopharmaceutical investment. Major trends in the forecast period include immunotherapy advancements, subcutaneous administration, next-generation antibodies, subcutaneous formulations, digital health integration, advancements in biotechnology.

The increasing prevalence of cost-efficient biosimilar monoclonal antibodies is driving the monoclonal antibody market’s growth. The biosimilars’ aim is to curb the increasing cost of healthcare and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilars are pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. A biosimilar monoclonal antibody costs 20%–25% less than the original biologic drug. The number of clinical trials for a biosimilar is comparatively smaller than that of the original biologic drug, and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2554&type=smp

The monoclonal antibodies (mabs) market covered in this report is segmented –
1) By Source: Murine, Chimeric, Humanized, Human
2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications
3) By End Users: Hospitals, Private Clinics, Research Institute

Biodegradable polymer technology is a key trend gaining popularity in the MS polymer market. Major companies operating in the MS polymer market are developing innovative and sustainable technologies to strengthen their position in the market. For instance, in February 2023, Kaneka Corporation, a Japan-based chemical manufacturing company, launched Biodegradable Polymer Green Planet, a plant-derived biodegradable polymer developed using polymer synthesis technology with microorganisms using CO2 as a direct raw material. By creating microorganisms that make biodegradable polymers from CO2, the technology aims to realize recycling-oriented bio manufacturing technology that is independent of fossil resources.

The monoclonal antibodies (mas) market report table of contents includes:
1. Executive Summary
2. Monoclonal Antibodies (MAs) Market Characteristics
3. Monoclonal Antibodies (MAs) Market Trends And Strategies
4. Monoclonal Antibodies (MAs) Market – Macro Economic Scenario
5. Global Monoclonal Antibodies (MAs) Market Size and Growth
…………………….
31. Global Monoclonal Antibodies (MAs) Market Competitive Benchmarking
32. Global Monoclonal Antibodies (MAs) Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAs) Market
34. Monoclonal Antibodies (MAs) Market Future Outlook and Potential Analysis
35. Appendix

Read Related Topics:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model